Orvil Martinez, MD
General Practice · San Juan, PRNPI 1861649709
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (39.3%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Novartis at 45.9% of the total. Reporting peaked in 2024 at $2,401 and has fallen 93.8% since, to $150 in 2025. Among general practice clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 76 payments — averaging $91.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$3K
- Merck$2K
- Boehringer Ingelheim$669
- AstraZeneca$553
- Johnson & Johnson$510
- Sanofi-aventis U.S. LLC$294
- plus $194 from 4 others
Across 31 payments — averaging $6632.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$123K
- Pfizer$29K
- Eli Lilly Export S.A. Puerto Rico Branch$29K
- Teva Pharmaceuticals USA, Inc.$18K
- Taro Pharmaceuticals USA, Inc.$4K
- Eli Lilly$2K
What the payments were for
- Consulting fees$1,50022%
- Travel & lodging$2,72439%
- Food & beverage$2,69439%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 8 | $3,183 |
| Merck | 3 | $1,529 |
| Boehringer Ingelheim | 10 | $669 |
| AstraZeneca | 27 | $553 |
| Johnson & Johnson | 12 | $510 |
| Sanofi-aventis U.S. LLC | 7 | $294 |
| Novo Nordisk | 5 | $107 |
| Eli Lilly Export S.A. Puerto Rico Branch | 2 | $48 |
| PBG Puerto Rico LLC | 1 | $20 |
| Abbott | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,932 in reported general payments places this provider in the 95th percentile of 3,586 general practice providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 63 | $44,057 |
| JardianceEmpagliflozin | 44 | $42,481 |
| SynjardyEmpagliflozin/Metformin Hcl | 43 | $28,778 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 42 | $27,298 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 26 | $18,540 |
| EliquisApixaban | 25 | $17,247 |
| JanuviaSitagliptin Phosphate | 20 | $16,801 |
| SynthroidLevothyroxine Sodium | 221 | $16,096 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 17 | $11,715 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 34 | $8,126 |
| LantusInsulin Glargine,hum.Rec.Anlog | 88 | $7,862 |
| Spiriva RespimatTiotropium Bromide | 14 | $7,456 |
| JentaduetoLinagliptin/Metformin Hcl | 13 | $6,853 |
| BrilintaTicagrelor | 16 | $6,817 |
| HumalogInsulin Lispro | 36 | $5,293 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy, Trijardy Xr, Synjardy Xr, Spiriva Respimat | $669 | $115,823157 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $553 | $55,58899 claims |
| MerckJanumet Xr, Januvia | $1,529 | $44,10062 claims |
| Sanofi-aventis U.S. LLCLantus | $294 | $7,86288 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,586 general practice providers in Puerto Rico.
Other general practice in San Juan
- William E TorresSan Juan$86K
- Vivian Tamayo AgraitSan Juan$64K
- Gregorio Cortes-MaisonetSan Juan$26K
- Victor PalmerSan Juan$21K
- Jose Davila SanchezSan Juan$16K
- Hector Cintron ColonSan Juan$10K
- Gabriela TorresSan Juan$8K
- Carlos Henriquez FelipeSan Juan$6K
- Rene Echevarria CofinoSan Juan$6K
- Luis Marquez BabiloniaSan Juan$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.